Rimonabant on Weight Reduction and Weight Maintenance: RIO-NORTH AMERICA - RIO-NA

Description:

The goal of the trial was to evaluate the efficacy and safety of Rimonabant, the first selective cannabinoid type 1 (CB1) receptor antagonist, compared with placebo for weight reduction out to two years.